ITCI:NGS-Intra-Cellular Therapies Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 88.49

Change

-3.08 (-3.36)%

Market Cap

USD 0.57B

Volume

0.79M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.07 (+0.54%)

USD 13.87B
NBIX Neurocrine Biosciences Inc

-1.50 (-1.18%)

USD 12.37B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
HCM HUTCHMED DRC

-0.44 (-2.52%)

USD 3.18B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
SUPN Supernus Pharmaceuticals Inc

-0.06 (-0.16%)

USD 1.93B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B
KNSA Kiniksa Pharmaceuticals Ltd

-0.37 (-1.61%)

USD 1.59B

ETFs Containing ITCI

PSIL AdvisorShares Psychedelic.. 4.46 % 0.00 %

-0.24 (-1.26%)

USD 6.37M
IBRN iShares Trust - iShares N.. 4.16 % 0.00 %

-0.35 (-1.26%)

USD 4.01M
FBT:LSE First Trust Global Funds .. 3.79 % 0.00 %

+5.20 (+-1.26%)

USD 8.45M
FBTU:LSE First Trust Global Funds .. 3.79 % 0.00 %

-0.06 (-1.26%)

USD 8.45M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.55% 79% B- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.55% 79% B- 75% C
Trailing 12 Months  
Capital Gain 56.07% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.07% 83% B 83% B
Trailing 5 Years  
Capital Gain 901.02% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 901.02% 100% F 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 40.44% 76% C+ 85% B
Dividend Return 40.44% 76% C+ 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.31% 71% C- 52% F
Risk Adjusted Return 111.39% 100% F 98% N/A
Market Capitalization 0.57B 97% N/A 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 8.01 22% 16%
Price / Cash Flow Ratio -73.87 97% 95%
Price/Free Cash Flow Ratio -37.12 97% 95%
Management Effectiveness  
Return on Equity -9.90% 65% 50%
Return on Invested Capital -25.65% 41% 31%
Return on Assets -7.45% 46% 38%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.